Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Abstract Introduction The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regim...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Nancy Reau, Wei-Han Cheng, Qiujun Shao, Steven E. Marx, Hannah Brooks, Anthony Martinez
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2023-06-01
Serie:	Infectious Diseases and Therapy
Soggetti:	Compensated cirrhosis Glecaprevir Pibrentasvir Hepatitis C virus Infectious diseases Treatment naïve
Accesso online:	https://doi.org/10.1007/s40121-023-00823-z
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!